Background Urotensin Ⅱ (UⅡ) is a new vasoconstrictive peptide that may activate the adventitial fibroblasts.Transforming growth factor-β1 (TGF-β1) is an imp
Background Tissue-engineered bioartificial muscle-based gene therapy represents a promising approach for the treatment of heart diseases. Experimental and clini